A promising therapy that may slow or stop Parkinson’s progression is moving forward. The Michael J. Fox Foundation (MJFF) announced plans to collaborate to assess the clinical use and development of cancer drug nilotinib. Among the partners’ goals: planning a double-blind, placebo-controlled clinical trial of nilotinib.
What has the research told us about nilotinib?
Two studies in pre-clinical PD models from 2013 and 2014 showed protective effects of nilotinib. And several other studies in pre-clinical PD models have shown protective effects of inhibiting c-Abl. This provided impetus for testing nilotinib in patients.
The trial results from a small, open-label (all knew they were getting the drug) trial of nilotinib in people with advanced Parkinson’s — included impact on spinal fluid measures of alpha-synuclein and imaging scans of dopamine function.
The drug was well tolerated, and participants reported improvements in motor skills and cognitive function. These are encouraging results; unfortunately, researchers know that the likelihood of placebo effect is high in any open-label Parkinson’s clinical study. Nonetheless, MJFF deems these findings supportive of continued, rigorous research in this area.
Should patients start taking nilotinib?
In short, no. We just don’t know enough yet.
To find out more about eligibility for the study, contact :
Albany Medical College
Albany, New York, United States, 12208
Contact: Darryl Collins 518-262-6651 firstname.lastname@example.org
Contact: Sharon Evans 518-262-6682 email@example.com
Principal Investigator: Eric Molho, MD
Read more about the drug :